In-Clinic and Natural Gait Observations master protocol (I-CAN-GO) to validate gait using a lumbar accelerometer-Reference-Cited by-同舟云学术

In-Clinic and Natural Gait Observations master protocol (I-CAN-GO) to validate gait using a lumbar accelerometer

Published:2024-08-29 Issue:1 Volume:14 Page:
ISSN:2045-2322
Container-title:Scientific Reports
language:en
Short-container-title:Sci Rep

Author:

Welbourn Miles,Sheriff Paul,Tuttle Pirinka Georgiev,Adamowicz Lukas,Psaltos Dimitrios,Kelekar Amey,Selig Jessica,Messere Andrew,Mei Winnie,Caouette David,Ghafoor Sana,Santamaria Mar,Zhang Hao,Demanuele Charmaine,Karahanoglu F. Isik,Cai Xuemei

Funder

Pfizer,United States

Publisher

Springer Science and Business Media LLC

Link

https://www.nature.com/articles/s41598-024-67675-6.pdf

Reference70 articles.

1. Hardy, S. E., Perera, S., Roumani, Y. F., Chandler, J. M. & Studenski, S. A. Improvement in usual gait speed predicts better survival in older adults. J. Am. Geriatr. Soc. 55, 1727–1734 (2007).

2. Kan, G. A. V. et al. Gait speed at usual pace as a predictor of adverse outcomes in community-dwelling older people an International Academy on Nutrition and Aging (IANA) Task Force. J. Nutr. Heal Aging 13, 881–889 (2009).

3. Hornyak, V., VanSwearingen, J. M. & Brach, J. S. Measurement of gait speed. Top. Geriatr. Rehabilitation 28, 27–32 (2012).

4. Pirker, W. & Katzenschlager, R. Gait disorders in adults and the elderly. Wien. Klin. Wochenschr. 129, 81–95 (2017).

5. European Medicines Agency. Final Qualification Opinion for Stride velocity 95th centile as primary endpoint in studies in ambulatory Duchenne Muscular Dystrophy studies. https://www.ema.europa.eu/en/documents/scientific-guideline/qualification-opinion-stride-velocity-95th-centile-primary-endpoint-studies-ambulatory-duchenne_en.pdf.